EMEA supports safety of thiomersal-containing vaccines

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1432-1433, 2004-01, pp. : 21-21

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

When science is not enough – a risk/benefit profile of thiomersal-containing vaccines

By Clements C John McIntyre Peter B

Expert Opinion on Drug Safety, Vol. 5, Iss. 1, 2006-01 ,pp. : 17-29

Informa Healthcare

Access to resources Recommend Favorite

The benefit-risk balance of thiomersal-containing vaccines remains overwhelmingly positive

Inpharma, Vol. 1, Iss. 1376, 2003-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Thiomersal in Vaccines: Is Removal Warranted?

By Clements C.

Drug Safety, Vol. 24, Iss. 8, 2001-01 ,pp. : 567-574

Adis International

Access to resources Recommend Favorite

Infliximab: safety update from EMEA

Inpharma, Vol. 1, Iss. 1324, 2002-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Thiomersal in Vaccines: Balancing the Risk of Adverse Effects with the Risk of Vaccine-Preventable Disease

By Mark Bigham Ray Copes

Drug Safety, Vol. 28, Iss. 2, 2005-01 ,pp. : 89-101

Adis International

Access to resources Recommend Favorite